Retrospective evaluation of the clinical and radiographic risk factors associated with severe pulmonary hemorrhage in first-line advanced, unresectable non-small-cell lung cancer treated with carboplatin and paclitaxel plus bevacizumab

Alan B. Sandler, Joan H. Schiller, Robert Gray, Isaiah Dimery, Julie Brahmer, Meghna Samant, Lisa I. Wang, David H. Johnson

Research output: Contribution to journalArticle

133 Citations (Scopus)

Abstract

Purpose Severe (grade ≤ 3) pulmonary hemorrhage (PH) in advanced non-small-cell lung cancer was observed in two prospective, randomized, phase II (N = 99) and phase III (N = 878) trials of bevacizumab plus carboplatin and paclitaxel. Retrospective case-control and cohort analyses were conducted to identify associated radiographic and clinical risk factors for PH. Patients and Methods Six patients with PH from the phase II trial, 15 potential PH patients with hemorrhage at any site from the phase III trial, and their matched controls were evaluated with review of baseline and on-treatment radiographs by an independent radiology facility, blinded to patient/control status. Patients with severe (grade ≤ 3) PH from each trial were matched with up to three controls based on sex, age group, histology (phase II), or sex and age group (phase III). Results Seven PH patients in the phase III trial were identified as severe PH. Six of the patients were early onset (occurred < 150 days of initiating bevacizumab) and one was late onset. Baseline tumor cavitation, not tumor location, was identified as the only potential risk factor for patients with early onset. Combined analysis of severe PH patients from the phase II and phase III trials (n = 13), compared with their pooled matched controls (n = 42), did not identify any additional baseline radiographic or clinical variables associated with PH. Conclusion PH was an uncommon event. Based on these analyses, baseline tumor cavitation may be a potential risk factor for PH. No other baseline clinical variables were predictive for PH although the number of events was small.

Original languageEnglish (US)
Pages (from-to)1405-1412
Number of pages8
JournalJournal of Clinical Oncology
Volume27
Issue number9
DOIs
StatePublished - Mar 20 2009

Fingerprint

Carboplatin
Paclitaxel
Non-Small Cell Lung Carcinoma
Hemorrhage
Lung
Bevacizumab
Age Groups
Neoplasms
Radiology
Histology
Cohort Studies

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Medicine(all)

Cite this

Retrospective evaluation of the clinical and radiographic risk factors associated with severe pulmonary hemorrhage in first-line advanced, unresectable non-small-cell lung cancer treated with carboplatin and paclitaxel plus bevacizumab. / Sandler, Alan B.; Schiller, Joan H.; Gray, Robert; Dimery, Isaiah; Brahmer, Julie; Samant, Meghna; Wang, Lisa I.; Johnson, David H.

In: Journal of Clinical Oncology, Vol. 27, No. 9, 20.03.2009, p. 1405-1412.

Research output: Contribution to journalArticle

@article{aeff028fcf1443b1ae6f8d5f395c3951,
title = "Retrospective evaluation of the clinical and radiographic risk factors associated with severe pulmonary hemorrhage in first-line advanced, unresectable non-small-cell lung cancer treated with carboplatin and paclitaxel plus bevacizumab",
abstract = "Purpose Severe (grade ≤ 3) pulmonary hemorrhage (PH) in advanced non-small-cell lung cancer was observed in two prospective, randomized, phase II (N = 99) and phase III (N = 878) trials of bevacizumab plus carboplatin and paclitaxel. Retrospective case-control and cohort analyses were conducted to identify associated radiographic and clinical risk factors for PH. Patients and Methods Six patients with PH from the phase II trial, 15 potential PH patients with hemorrhage at any site from the phase III trial, and their matched controls were evaluated with review of baseline and on-treatment radiographs by an independent radiology facility, blinded to patient/control status. Patients with severe (grade ≤ 3) PH from each trial were matched with up to three controls based on sex, age group, histology (phase II), or sex and age group (phase III). Results Seven PH patients in the phase III trial were identified as severe PH. Six of the patients were early onset (occurred < 150 days of initiating bevacizumab) and one was late onset. Baseline tumor cavitation, not tumor location, was identified as the only potential risk factor for patients with early onset. Combined analysis of severe PH patients from the phase II and phase III trials (n = 13), compared with their pooled matched controls (n = 42), did not identify any additional baseline radiographic or clinical variables associated with PH. Conclusion PH was an uncommon event. Based on these analyses, baseline tumor cavitation may be a potential risk factor for PH. No other baseline clinical variables were predictive for PH although the number of events was small.",
author = "Sandler, {Alan B.} and Schiller, {Joan H.} and Robert Gray and Isaiah Dimery and Julie Brahmer and Meghna Samant and Wang, {Lisa I.} and Johnson, {David H.}",
year = "2009",
month = "3",
day = "20",
doi = "10.1200/JCO.2008.16.2412",
language = "English (US)",
volume = "27",
pages = "1405--1412",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "9",

}

TY - JOUR

T1 - Retrospective evaluation of the clinical and radiographic risk factors associated with severe pulmonary hemorrhage in first-line advanced, unresectable non-small-cell lung cancer treated with carboplatin and paclitaxel plus bevacizumab

AU - Sandler, Alan B.

AU - Schiller, Joan H.

AU - Gray, Robert

AU - Dimery, Isaiah

AU - Brahmer, Julie

AU - Samant, Meghna

AU - Wang, Lisa I.

AU - Johnson, David H.

PY - 2009/3/20

Y1 - 2009/3/20

N2 - Purpose Severe (grade ≤ 3) pulmonary hemorrhage (PH) in advanced non-small-cell lung cancer was observed in two prospective, randomized, phase II (N = 99) and phase III (N = 878) trials of bevacizumab plus carboplatin and paclitaxel. Retrospective case-control and cohort analyses were conducted to identify associated radiographic and clinical risk factors for PH. Patients and Methods Six patients with PH from the phase II trial, 15 potential PH patients with hemorrhage at any site from the phase III trial, and their matched controls were evaluated with review of baseline and on-treatment radiographs by an independent radiology facility, blinded to patient/control status. Patients with severe (grade ≤ 3) PH from each trial were matched with up to three controls based on sex, age group, histology (phase II), or sex and age group (phase III). Results Seven PH patients in the phase III trial were identified as severe PH. Six of the patients were early onset (occurred < 150 days of initiating bevacizumab) and one was late onset. Baseline tumor cavitation, not tumor location, was identified as the only potential risk factor for patients with early onset. Combined analysis of severe PH patients from the phase II and phase III trials (n = 13), compared with their pooled matched controls (n = 42), did not identify any additional baseline radiographic or clinical variables associated with PH. Conclusion PH was an uncommon event. Based on these analyses, baseline tumor cavitation may be a potential risk factor for PH. No other baseline clinical variables were predictive for PH although the number of events was small.

AB - Purpose Severe (grade ≤ 3) pulmonary hemorrhage (PH) in advanced non-small-cell lung cancer was observed in two prospective, randomized, phase II (N = 99) and phase III (N = 878) trials of bevacizumab plus carboplatin and paclitaxel. Retrospective case-control and cohort analyses were conducted to identify associated radiographic and clinical risk factors for PH. Patients and Methods Six patients with PH from the phase II trial, 15 potential PH patients with hemorrhage at any site from the phase III trial, and their matched controls were evaluated with review of baseline and on-treatment radiographs by an independent radiology facility, blinded to patient/control status. Patients with severe (grade ≤ 3) PH from each trial were matched with up to three controls based on sex, age group, histology (phase II), or sex and age group (phase III). Results Seven PH patients in the phase III trial were identified as severe PH. Six of the patients were early onset (occurred < 150 days of initiating bevacizumab) and one was late onset. Baseline tumor cavitation, not tumor location, was identified as the only potential risk factor for patients with early onset. Combined analysis of severe PH patients from the phase II and phase III trials (n = 13), compared with their pooled matched controls (n = 42), did not identify any additional baseline radiographic or clinical variables associated with PH. Conclusion PH was an uncommon event. Based on these analyses, baseline tumor cavitation may be a potential risk factor for PH. No other baseline clinical variables were predictive for PH although the number of events was small.

UR - http://www.scopus.com/inward/record.url?scp=63049122188&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=63049122188&partnerID=8YFLogxK

U2 - 10.1200/JCO.2008.16.2412

DO - 10.1200/JCO.2008.16.2412

M3 - Article

C2 - 19224857

AN - SCOPUS:63049122188

VL - 27

SP - 1405

EP - 1412

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 9

ER -